Ameliorated Pap Tests and Cervical Cancer Screening Participation
NCT ID: NCT06968871
Last Updated: 2025-11-14
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
NOT_YET_RECRUITING
Clinical Phase
NA
Total Enrollment
248 participants
Study Classification
INTERVENTIONAL
Study Start Date
2026-01-01
Study Completion Date
2032-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The Pap test plays a crucial role in the early detection of cervical cancer. A pilot single-center randomized controlled trial applied the peak-end concept and added a non-painful step at the end of Pap smear screening, aimed to reduce recalled pain. However, there is still no multicenter study investigating the effect of the modified Pap test on cervical cancer screening participation.
The present project is the first multicenter randomized controlled trial to expand the current scope of the peak-end theory into Pap tests and cervical cancer screening participation by adding a non-painful step at the end of Pap smear screening. Our multidisciplinary team (NTUH Pap Study Group) aims to provide innovative, feasible, and low-cost strategies for cervical cancer screening participation.
The present project is the first multicenter randomized controlled trial to expand the current scope of the peak-end theory into Pap tests and cervical cancer screening participation by adding a non-painful step at the end of Pap smear screening. Our multidisciplinary team (NTUH Pap Study Group) aims to provide innovative, feasible, and low-cost strategies for cervical cancer screening participation.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of Human Papillomavirus Integrated DNA and Messenger RNA in Cervical Neoplasia
NCT02198365
Cervical Intraepithelial Neoplasia
COMPLETED
Comparison of Screening Tests in Detecting Cervical Neoplasia
NCT00039312
Cervical Cancer
COMPLETED
NA
The Association Between Cervical Cancer Screening and Cancer Occurrence
NCT01015079
Cervical Cancer
Cancer
UNKNOWN
The Correlations Between HPV L1-Specific Immunologic Responses in Cervical Cancer and Cervical Intraepithelial Neoplasia (CIN) Patients and Their Prognosis
NCT00728871
Cervical Cancer
Cervical Intraepithelial Neoplasia
UNKNOWN
NA
Ameliorating the Obstacle of Pap Smear
NCT04420208
Pain
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participants: This project expects to include women just before they undergo Pap smear screening at the NTUH Healthcare System in 2026. We include eligible women aged 25 or above who have not yet undergone Pap tests in 2026. Excluded are those who have ongoing menstruation and those who are pregnant or incapable of understanding the numeric pain scales. Women who have any active cancer at study entry (defined as cancer diagnosed or treated within the previous 6 months, recurrent, regionally advanced or metastatic cancer), previous hysterectomy, previous pelvic surgery or radiotherapy, active vaginal or uterus infection, and analgesic use within 24 hours are excluded due to potential interference with pain intensity. The study protocol was approved by the NTUH Research Ethics Committee. During the recruitment process, every eligible participant is fully informed of this trial's aim, design, and content, except for the intervention details. All participants should provide written informed consent. This study is conducted according to the Declaration of Helsinki and is registered at ClinicalTrials.gov.
Sample size estimation: The investigators estimate to recruit at least 248 participants (180 at the NTUH, 68 at the NTUH Hsin-Chu, Bei-Hu, Yunlin, and Cancer Center branches), 50% (124) of whom are randomized to the intervention group, to reach 90% power for the detection of an increase in 3-year cervical cancer screening participation from 30% to 50% at the 5% level of significance.
Randomization and blinding: Eligible participants are randomly assigned to either the group receiving the traditional Pap test or the modified Pap test. Computer-generated random numbers are employed for simple randomization with a 1:1 allocation ratio. All participants are kept unaware of any information about group allocation throughout the study period. The operators performing the procedure are not informed by the assistants whether to intervene until a specimen is prepared for cervical cytology. The delayed disclosure of the group allocation until this step ensures that the operators standardize the insertion and opening phases of the Pap test. Cytopathologists who analyze the specimens are blinded to the study.
The modified and traditional Pap tests: All operators experienced in techniques for performing a Pap test should attend workshops for a standard operating procedure. The operators include family physicians and gynecologists. A well-trained research assistant is also responsible for ensuring standardization of procedures to eliminate interoperator variability. During the Pap test, there is a privacy curtain separating participants from the operators. An operator separates the labia with hand and then gently inserts the saline-lubricated speculum sideways. The speculum is rotated 90 degrees and opened to achieve an optimal view of the cervix. Then an operator fixes the speculum to obtain the cell samples by brushes. The above-standardized procedures are the same between the two groups. After preparing a specimen for conventional cytology, an operator loosens the locking nut of the speculum, partially closes the blade, rotates the speculum 90 degrees back to its original insertion orientation, and then removes the speculum in the control group receiving the traditional Pap test. For the intervention group receiving the modified Pap test, instead of immediately removing the speculum just after rotating back the speculum, an operator still fixes the speculum in the vagina for 15 seconds. Participants receiving the modified Pap test do not realize what is going on during the 15-second step because they are behind the privacy curtain. Procedurally, the subsequent addition of a non-painful step after specimen collection does not affect specimen quality.
Interview, Anthropometric Indices, and Anxiety scores: The investigators review the medical records after getting informed consent. In addition to pain evaluations, this project collects information about tobacco use, alcohol consumption, socioeconomic status, marital status, parity, sexually active status, menopause, predicted pain of Pap smears, psychological stress, anxiety score, analgesic use, current medications, and medical history through standardized personal interviews. Body height and weight are measured using a standard stadiometer, and body mass index is calculated. Blood pressure is measured with an electronic sphygmomanometer while the patient is seated after resting for at least five minutes. Psychological stress is assessed using the Brief Symptom Rating Scale -5 (BSRS-5). The BSRS-5 includes items of anxiety, depression, hostility, interpersonal sensitivity, and insomnia measured by a 5-point Likert-type scale of 0-4. Normal, slight, and great mental stress is defined by the sum of BSRS-5 scores ≤ 5, 6-9, and ≥10, respectively. The anxiety score is obtained using the Generalized Anxiety Disorder 7-item (GAD-7). GAD-7 total score for the seven items ranges from 0 to 21 (0-4: minimal anxiety. 5-9: mild anxiety. 10-14: moderate anxiety. 15-21: severe anxiety). Based on a meta-analysis, some experts have recommended considering using a cut-off of 8 to optimize sensitivity without compromising specificity.
Statistical analyses: For the descriptive analyses, values are presented as either numbers (percentages) or mean ± standard deviations. For the univariate analyses, categorical data are compared by the χ2 or Fisher's exact tests. Continuous data are compared using the independent T test. To compare screening uptake between trial groups, the investigators apply an ITT principle, such that outcomes are analyzed according to the trial groups assigned, regardless of whether the participants comply with the intervention components of each trial group. Logistic regression analyses are utilized to estimate the association of the intervention with the probability of 3-year and 1-year uptake of cervical cancer screening. The investigators use the five-region hypothesis test based on odds ratios to test the significant indistinguishability of real-time pain between the two groups for confirming the success of randomization and blinding. The effect sizes of five-minute recalled pain on a 1-5 numeric scale and a 0-10 VAS between the two groups are calculated using Glass's delta. Linear regression analyses are used to estimate the effect of the intervention on scores of 5-minute and 3-month recalled pains. Prespecified subgroup analyses using both linear and logistic regression analyses will be performed and summarized visually using forest plots. Major subgroups of interest include women who are never screened (never underwent Pap tests) and women who are under-screened (have not undergone Pap tests in the past 3 years). Statistical significance levels are determined by two-tailed tests (P \< 0.05). The statistical analyses are performed with SAS software version 9.4 (SAS Institute Inc., Cary, NC, USA).
Sample size estimation: The investigators estimate to recruit at least 248 participants (180 at the NTUH, 68 at the NTUH Hsin-Chu, Bei-Hu, Yunlin, and Cancer Center branches), 50% (124) of whom are randomized to the intervention group, to reach 90% power for the detection of an increase in 3-year cervical cancer screening participation from 30% to 50% at the 5% level of significance.
Randomization and blinding: Eligible participants are randomly assigned to either the group receiving the traditional Pap test or the modified Pap test. Computer-generated random numbers are employed for simple randomization with a 1:1 allocation ratio. All participants are kept unaware of any information about group allocation throughout the study period. The operators performing the procedure are not informed by the assistants whether to intervene until a specimen is prepared for cervical cytology. The delayed disclosure of the group allocation until this step ensures that the operators standardize the insertion and opening phases of the Pap test. Cytopathologists who analyze the specimens are blinded to the study.
The modified and traditional Pap tests: All operators experienced in techniques for performing a Pap test should attend workshops for a standard operating procedure. The operators include family physicians and gynecologists. A well-trained research assistant is also responsible for ensuring standardization of procedures to eliminate interoperator variability. During the Pap test, there is a privacy curtain separating participants from the operators. An operator separates the labia with hand and then gently inserts the saline-lubricated speculum sideways. The speculum is rotated 90 degrees and opened to achieve an optimal view of the cervix. Then an operator fixes the speculum to obtain the cell samples by brushes. The above-standardized procedures are the same between the two groups. After preparing a specimen for conventional cytology, an operator loosens the locking nut of the speculum, partially closes the blade, rotates the speculum 90 degrees back to its original insertion orientation, and then removes the speculum in the control group receiving the traditional Pap test. For the intervention group receiving the modified Pap test, instead of immediately removing the speculum just after rotating back the speculum, an operator still fixes the speculum in the vagina for 15 seconds. Participants receiving the modified Pap test do not realize what is going on during the 15-second step because they are behind the privacy curtain. Procedurally, the subsequent addition of a non-painful step after specimen collection does not affect specimen quality.
Interview, Anthropometric Indices, and Anxiety scores: The investigators review the medical records after getting informed consent. In addition to pain evaluations, this project collects information about tobacco use, alcohol consumption, socioeconomic status, marital status, parity, sexually active status, menopause, predicted pain of Pap smears, psychological stress, anxiety score, analgesic use, current medications, and medical history through standardized personal interviews. Body height and weight are measured using a standard stadiometer, and body mass index is calculated. Blood pressure is measured with an electronic sphygmomanometer while the patient is seated after resting for at least five minutes. Psychological stress is assessed using the Brief Symptom Rating Scale -5 (BSRS-5). The BSRS-5 includes items of anxiety, depression, hostility, interpersonal sensitivity, and insomnia measured by a 5-point Likert-type scale of 0-4. Normal, slight, and great mental stress is defined by the sum of BSRS-5 scores ≤ 5, 6-9, and ≥10, respectively. The anxiety score is obtained using the Generalized Anxiety Disorder 7-item (GAD-7). GAD-7 total score for the seven items ranges from 0 to 21 (0-4: minimal anxiety. 5-9: mild anxiety. 10-14: moderate anxiety. 15-21: severe anxiety). Based on a meta-analysis, some experts have recommended considering using a cut-off of 8 to optimize sensitivity without compromising specificity.
Statistical analyses: For the descriptive analyses, values are presented as either numbers (percentages) or mean ± standard deviations. For the univariate analyses, categorical data are compared by the χ2 or Fisher's exact tests. Continuous data are compared using the independent T test. To compare screening uptake between trial groups, the investigators apply an ITT principle, such that outcomes are analyzed according to the trial groups assigned, regardless of whether the participants comply with the intervention components of each trial group. Logistic regression analyses are utilized to estimate the association of the intervention with the probability of 3-year and 1-year uptake of cervical cancer screening. The investigators use the five-region hypothesis test based on odds ratios to test the significant indistinguishability of real-time pain between the two groups for confirming the success of randomization and blinding. The effect sizes of five-minute recalled pain on a 1-5 numeric scale and a 0-10 VAS between the two groups are calculated using Glass's delta. Linear regression analyses are used to estimate the effect of the intervention on scores of 5-minute and 3-month recalled pains. Prespecified subgroup analyses using both linear and logistic regression analyses will be performed and summarized visually using forest plots. Major subgroups of interest include women who are never screened (never underwent Pap tests) and women who are under-screened (have not undergone Pap tests in the past 3 years). Statistical significance levels are determined by two-tailed tests (P \< 0.05). The statistical analyses are performed with SAS software version 9.4 (SAS Institute Inc., Cary, NC, USA).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Cervical Cancer Screening
Cervical Cancer Screening Methods
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
SCREENING
Blinding Strategy
SINGLE
Participants
Cytopathologists who analyze the specimens are blinded to the study.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Traditional Pap test
Group Type
NO_INTERVENTION
No interventions assigned to this group
Modified Pap test
Group Type
EXPERIMENTAL
Modified Pap test
Intervention Type
PROCEDURE
For the intervention group receiving the modified Pap test, instead of immediately removing the speculum just after rotating back the speculum, an operator still fixes the speculum in the vagina for 15 seconds.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Modified Pap test
For the intervention group receiving the modified Pap test, instead of immediately removing the speculum just after rotating back the speculum, an operator still fixes the speculum in the vagina for 15 seconds.
Intervention Type
PROCEDURE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Women aged 25 or above
Exclusion Criteria
* Ongoing menstruation
* Pregnancy
* Incapability of understanding the numeric pain scales
* Any active cancer at study entry (defined as cancer diagnosed or treated within the previous 6 months, recurrent, regionally advanced or metastatic cancer)
* Previous hysterectomy, pelvic surgery, or radiotherapy
* Active vaginal or uterus infection
* Analgesic use within 24 hours
* Pregnancy
* Incapability of understanding the numeric pain scales
* Any active cancer at study entry (defined as cancer diagnosed or treated within the previous 6 months, recurrent, regionally advanced or metastatic cancer)
* Previous hysterectomy, pelvic surgery, or radiotherapy
* Active vaginal or uterus infection
* Analgesic use within 24 hours
Minimum Eligible Age
25 Years
Eligible Sex
FEMALE
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Taiwan University Hospital Hsin-Chu Branch
OTHER
Sponsor Role
collaborator
National Taiwan University
OTHER
Sponsor Role
collaborator
National Taiwan University Hospital Beihu Branch
OTHER
Sponsor Role
collaborator
National Taiwan University Hospital, Yun-Lin Branch
OTHER
Sponsor Role
collaborator
National Science and Technology Council
FED
Sponsor Role
collaborator
National Taiwan University Hospital
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Chien-Hsieh Chiang, MD, MPH, PhD
Role: STUDY_CHAIR
National Taiwan University Hospital & College of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Taiwan University Hospital Yunlin Branch
Douliu, , Taiwan
Site Status
National Taiwan University Hospital Hsin-Chu Branch
Hsinchu, , Taiwan
Site Status
National Taiwan University Hospital
Taipei, , Taiwan
Site Status
National Taiwan University Cancer Center
Taipei, , Taiwan
Site Status
National Taiwan University Hospital Beihu Branch
Taipei, , Taiwan
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Taiwan
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Uygur D, Guler T, Yayci E, Atacag T, Comunoglu C, Kuzey GM. Association of speculum lubrication with pain and Papanicolaou test accuracy. J Am Board Fam Med. 2012 Nov-Dec;25(6):798-804. doi: 10.3122/jabfm.2012.06.120021.
Reference Type
BACKGROUND
Keskin AE, Onaran Y, Duvan IC, Simavli S, Kafali H. Topical anesthetic (lidocaine-prilocaine) cream application before speculum examination in postmenopausal women. J Minim Invasive Gynecol. 2012 May-Jun;19(3):350-5. doi: 10.1016/j.jmig.2012.01.005. Epub 2012 Mar 13.
Reference Type
BACKGROUND
Simavli S, Kaygusuz I, Kinay T, Cukur S. The role of gel application in decreasing pain during speculum examination and its effects on papanicolaou smear results. Arch Gynecol Obstet. 2014 Apr;289(4):809-15. doi: 10.1007/s00404-013-3047-x. Epub 2013 Oct 12.
Reference Type
BACKGROUND
Leung SS, Leung I. Cervical cancer screening: knowledge, health perception and attendance rate among Hong Kong Chinese women. Int J Womens Health. 2010 Aug 9;2:221-8. doi: 10.2147/ijwh.s10724.
Reference Type
BACKGROUND
Song W, Li H, Sun F, Guo T, Jiang S, Wang X. Pain Avoidance and Its Relation to Neural Response to Punishment Characterizes Suicide Attempters with Major Depression Disorder. Psychiatry Res. 2020 Dec;294:113507. doi: 10.1016/j.psychres.2020.113507. Epub 2020 Oct 13.
Reference Type
BACKGROUND
Claes N, Crombez G, Vlaeyen JWS. Pain-avoidance versus reward-seeking: an experimental investigation. Pain. 2015 Aug;156(8):1449-1457. doi: 10.1097/j.pain.0000000000000116.
Reference Type
BACKGROUND
Gauss JW, Mabiso A, Williams KP. Pap screening goals and perceptions of pain among black, Latina, and Arab women: steps toward breaking down psychological barriers. J Cancer Educ. 2013 Jun;28(2):367-74. doi: 10.1007/s13187-012-0441-1.
Reference Type
BACKGROUND
Hoyo C, Yarnall KS, Skinner CS, Moorman PG, Sellers D, Reid L. Pain predicts non-adherence to pap smear screening among middle-aged African American women. Prev Med. 2005 Aug;41(2):439-45. doi: 10.1016/j.ypmed.2004.11.021.
Reference Type
BACKGROUND
Masson H. Cervical pap smears and pandemics: The effect of COVID-19 on screening uptake & opportunities to improve. Womens Health (Lond). 2021 Jan-Dec;17:17455065211017070. doi: 10.1177/17455065211017070.
Reference Type
BACKGROUND
Holroyd E, Twinn S, Adab P. Socio-cultural influences on Chinese women's attendance for cervical screening. J Adv Nurs. 2004 Apr;46(1):42-52. doi: 10.1111/j.1365-2648.2003.02964.x.
Reference Type
BACKGROUND
Kaneko N. Factors associated with cervical cancer screening among young unmarried Japanese women: results from an internet-based survey. BMC Womens Health. 2018 Jul 31;18(1):132. doi: 10.1186/s12905-018-0623-z.
Reference Type
BACKGROUND
Friedman AM, Hemler JR, Rossetti E, Clemow LP, Ferrante JM. Obese women's barriers to mammography and pap smear: the possible role of personality. Obesity (Silver Spring). 2012 Aug;20(8):1611-7. doi: 10.1038/oby.2012.50. Epub 2012 Feb 28.
Reference Type
BACKGROUND
Jhuang JR, Lee WC, Chan CC. A randomized, double-blind water taste test to evaluate the equivalence of taste between tap water and filtered water in the Taipei metropolis. Sci Rep. 2020 Aug 7;10(1):13387. doi: 10.1038/s41598-020-70272-y.
Reference Type
BACKGROUND
Shih HY, Lee WC. A Five-Region Hypothesis Test for Exposure-Disease Associations. Sci Rep. 2017 Jul 11;7(1):5131. doi: 10.1038/s41598-017-05301-4.
Reference Type
BACKGROUND
Plummer F, Manea L, Trepel D, McMillan D. Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic metaanalysis. Gen Hosp Psychiatry. 2016 Mar-Apr;39:24-31. doi: 10.1016/j.genhosppsych.2015.11.005. Epub 2015 Nov 18.
Reference Type
BACKGROUND
Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006 May 22;166(10):1092-7. doi: 10.1001/archinte.166.10.1092.
Reference Type
BACKGROUND
Chen HC, Wu CH, Lee YJ, Liao SC, Lee MB. Validity of the five-item Brief Symptom Rating Scale among subjects admitted for general health screening. J Formos Med Assoc. 2005 Nov;104(11):824-9.
Reference Type
BACKGROUND
Chen CJ, Hong MK, Ding DC. Effective reduction in inadequate Pap smears by using a saline-lubricated speculum and two glass slides. Taiwan J Obstet Gynecol. 2020 Nov;59(6):906-909. doi: 10.1016/j.tjog.2020.09.018.
Reference Type
BACKGROUND
Sandkuhler J, Lee J. How to erase memory traces of pain and fear. Trends Neurosci. 2013 Jun;36(6):343-52. doi: 10.1016/j.tins.2013.03.004. Epub 2013 Apr 18.
Reference Type
BACKGROUND
Yen HK, Cheng SY, Chiu KN, Huang CC, Yu JY, Chiang CH; NTUH Pap Study Group. Adding a nonpainful end to reduce pain recollection of Pap smear screening: a randomized controlled trial. Pain. 2023 Aug 1;164(8):1709-1717. doi: 10.1097/j.pain.0000000000002897. Epub 2023 Apr 12.
Reference Type
BACKGROUND
Hsu CF, Propp L, Panetta L, Martin S, Dentakos S, Toplak ME, Eastwood JD. Mental effort and discomfort: Testing the peak-end effect during a cognitively demanding task. PLoS One. 2018 Feb 12;13(2):e0191479. doi: 10.1371/journal.pone.0191479. eCollection 2018.
Reference Type
BACKGROUND
Muller UWD, Witteman CLM, Spijker J, Alpers GW. All's Bad That Ends Bad: There Is a Peak-End Memory Bias in Anxiety. Front Psychol. 2019 Jun 12;10:1272. doi: 10.3389/fpsyg.2019.01272. eCollection 2019.
Reference Type
BACKGROUND
Schneider S, Stone AA, Schwartz JE, Broderick JE. Peak and end effects in patients' daily recall of pain and fatigue: a within-subjects analysis. J Pain. 2011 Feb;12(2):228-35. doi: 10.1016/j.jpain.2010.07.001.
Reference Type
BACKGROUND
Arney J, Hinojosa-Lindsey M, Street RL Jr, Hou J, El-Serag HB, Naik AD. Patient experiences with surveillance endoscopy: a qualitative study. Dig Dis Sci. 2014 Jul;59(7):1378-85. doi: 10.1007/s10620-014-3035-4. Epub 2014 Feb 6.
Reference Type
BACKGROUND
Redelmeier DA, Katz J, Kahneman D. Memories of colonoscopy: a randomized trial. Pain. 2003 Jul;104(1-2):187-94. doi: 10.1016/s0304-3959(03)00003-4.
Reference Type
BACKGROUND
Redelmeier DA, Kahneman D. Patients' memories of painful medical treatments: real-time and retrospective evaluations of two minimally invasive procedures. Pain. 1996 Jul;66(1):3-8. doi: 10.1016/0304-3959(96)02994-6.
Reference Type
BACKGROUND
Vlaeyen JWS, Linton SJ. Fear-avoidance and its consequences in chronic musculoskeletal pain: a state of the art. Pain. 2000 Apr;85(3):317-332. doi: 10.1016/S0304-3959(99)00242-0.
Reference Type
BACKGROUND
Lin SN, Taylor J, Alperstein S, Hoda R, Holcomb K. Does speculum lubricant affect liquid-based Papanicolaou test adequacy? Cancer Cytopathol. 2014 Mar;122(3):221-6. doi: 10.1002/cncy.21369. Epub 2013 Nov 19.
Reference Type
BACKGROUND
Chou HH, Huang HJ, Cheng HH, Chang CJ, Yang LY, Huang CC, Chang WY, Hsueh S, Chao A, Wang CJ, Tang YH, Lin CT, Qiu JT, Chen MY, Chen CY, Huang KG, Tsai TC, Chang TC, Lai CH. Self-sampling HPV test in women not undergoing Pap smear for more than 5 years and factors associated with under-screening in Taiwan. J Formos Med Assoc. 2016 Dec;115(12):1089-1096. doi: 10.1016/j.jfma.2015.10.014. Epub 2015 Dec 23.
Reference Type
BACKGROUND
Yang CM, Sung FC, Hsue CS, Muo CH, Wang SW, Shieh SH. Comparisons of Papanicolaou Utilization and Cervical Cancer Detection between Rural and Urban Women in Taiwan. Int J Environ Res Public Health. 2020 Dec 28;18(1):149. doi: 10.3390/ijerph18010149.
Reference Type
BACKGROUND
Sirovich BE, Welch HG. The frequency of Pap smear screening in the United States. J Gen Intern Med. 2004 Mar;19(3):243-50. doi: 10.1111/j.1525-1497.2004.21107.x.
Reference Type
BACKGROUND
Dugue PA, Lynge E, Rebolj M. Mortality of non-participants in cervical screening: Register-based cohort study. Int J Cancer. 2014 Jun 1;134(11):2674-82. doi: 10.1002/ijc.28586. Epub 2013 Nov 29.
Reference Type
BACKGROUND
Andrae B, Andersson TM, Lambert PC, Kemetli L, Silfverdal L, Strander B, Ryd W, Dillner J, Tornberg S, Sparen P. Screening and cervical cancer cure: population based cohort study. BMJ. 2012 Mar 1;344:e900. doi: 10.1136/bmj.e900.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
202502041RINE
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Evaluating the Impact of Different Methods of HPV DNA Testing for Cervical Cancer Screening in Primary Care Settings
NCT06528184
RECRUITING
NA
HPV Integration Testing for Human Papillomavirus-Positive Women
NCT02576262
UNKNOWN
Accurate Screening and Prevention of Cervical Lesions-- Development of Accurate Screening Methods for Cervical Lesions
NCT05851079
UNKNOWN
Digital Colposcopy in Finding Cervical Intraepithelial Neoplasia in Patients With An Abnormal Pap Smear
NCT00610662
WITHDRAWN
Cervical Cancer Screening with NGS-HPV Technology Based on Menstrual Blood
NCT06082765
RECRUITING
Screening for Early Cervical Cancer Detection
NCT06550583
ACTIVE_NOT_RECRUITING
Detection of Biomarkers in Abnormal Cervical Cells in Women With Abnormal Pap Test Results
NCT00004091
COMPLETED
HPV Integration Testing for Cervical Cancer Screening
NCT02576158
UNKNOWN
Comparing Strategies for Implementing Primary HPV Screening
NCT04371887
UNKNOWN
NA
102 Annual Pap Smear Screening Database Maintenance Project
NCT02063152
UNKNOWN
Spectroscopy Versus Standard Care in Cervical Cancer Patients
NCT00529464
TERMINATED
PHASE3
Cervical Cancer Screening Strategies
NCT05309122
UNKNOWN
Comparisons of the Effects and Clinical Outcomes of CH2 Vaginal Gel Versus Placebo on CIN1
NCT06582004
ACTIVE_NOT_RECRUITING
NA
Clinical Evaluation of HPV Integration Triage for Detection of Cervical Precancer in HPV-positive Women
NCT05570331
RECRUITING
Effect of Human Papillomavirus Self-Collection on Cervical Cancer Screening in High Risk Women: My Body, My Test 3
NCT02651883
COMPLETED
NA
Screening for Cervical Intraepithelial Neoplasia Using Self-collected Menstrual Blood
NCT03638427
COMPLETED
Spectroscopy and Artificial Intelligence to Disrupt the Status Quo in Cervical Cancer Screening
NCT05236855
UNKNOWN
Study of Pap Smears From Patients Enrolled on Clinical Trial GOG-171
NCT00898144
UNKNOWN
Pilot Study for Speculum Free Cervical Cancer Screening
NCT04107181
RECRUITING
NA
Digital Colposcopy in Finding Cervical Intraepithelial Neoplasia
NCT00602368
COMPLETED
NA
Self-Testing Options in the Era of Primary HPV Screening for Cervical Cancer Trial
NCT04679675
COMPLETED
NA
Cervical Intraepithelial Neoplasia Screening Using Liquid-Based Pap Smear Among Egyptian Women
NCT07250841
COMPLETED
CervIcal Cancer Screening Trial by Randomization of HPV Testing Intervention for Upcoming Screening （CITRUS Study）
NCT01895517
COMPLETED
PHASE4
Feasibility and Acceptability of Offering Self-sampling to Non-attendees in Primary Care
NCT02698423
COMPLETED
NA
Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S01)
NCT06498661
ACTIVE_NOT_RECRUITING
NA